Home › Companies › ULTRAGENYX PHARMACEUTICAL INC. › 2023-2024
Compiled from SEC Form N-PX filings and ULTRAGENYX PHARMACEUTICAL INC.’s Form 8-K, filed 2024-06-21 (Item 5.07 on EDGAR). Page generated 02 October 2026.
Explore ULTRAGENYX PHARMACEUTICAL INC. in the interactive database Compare manager voting policies
These tallies are ULTRAGENYX PHARMACEUTICAL INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-06-21 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Deborah Dunsire, M.D. | 66,396,499 | -- | -- | 7,865,348 | 4,273,815 | Majority: yes |
| Elect Director: Michael Narachi | 66,013,202 | -- | -- | 8,248,645 | 4,273,815 | Majority: yes |
| Elect Director: Corsee Sanders, Ph.D. | 68,077,817 | -- | -- | 6,184,030 | 4,273,815 | Majority: yes |
| Proposal 2: Approval of the A&R 2023 Plan At the Annual Meeting, the Company's stockholders approved the A&R 2023 Plan. The votes on Proposal 2 were as follows: | 51,942,752 | 22,299,718 | 19,377 | -- | 4,273,815 | Majority: yes |
| Proposal 3: Ratification of Selection of Independent Registered Accounting Firm At the Annual Meeting, the Company's stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal yea | 77,155,452 | 1,362,194 | 18,016 | -- | -- | Majority: yes |
| Proposal 4: Advisory (Non-Binding) Vote to Approve Executive Compensation At the Annual Meeting, the Company's stockholders voted, on an advisory basis, in favor of a resolution approving the compensation the Company pays to its "named executive officers" as d | 54,803,351 | 19,320,182 | 138,314 | -- | 4,273,815 | Majority: yes |
Source: ULTRAGENYX PHARMACEUTICAL INC., Form 8-K, filed with the SEC on 2024-06-21 — read the filing on EDGAR.
Each item below shows how the 324 asset managers that disclosed a ULTRAGENYX PHARMACEUTICAL INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of ULTRAGENYX PHARMACEUTICAL INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 9 wordings of this item as funds reported it.
74% Majority: yes · of votes cast
ULTRAGENYX PHARMACEUTICAL INC.’s own tally for this item (“Proposal 4: Advisory (Non-Binding) Vote to Approve Executive Compensation At the Annual Meeting, the Company's stockholders voted, on an advisory basis, in favor of a resolution approving the compensation the Company pay”): 54,803,351 for, 19,320,182 against, per its Form 8-K filed 2024-06-21 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 83,094,037 outstanding shares: 66% for, 23% against (89% of the company cast a for/against vote).
The 320 asset managers below cast 74% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the company's reported shares outstanding.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 9,770,199 | 741,418 | 0 | 0 | For |
| RTW INVESTMENTS, LP | 6,742,286 | 0 | 0 | 0 | For |
| T. Rowe Price | 5,921,157 | 0 | 0 | 0 | For |
| BlackRock | 4,164,715 | 19,967 | 0 | 0 | For |
| State Street | 4,072,508 | 39,259 | 0 | 0 | For |
| Federated Hermes | 3,764,704 | 0 | 0 | 0 | For |
| Wellington | 3,746,452 | 0 | 0 | 0 | For |
| Fidelity | 2,894,644 | 21,749 | 0 | 0 | For |
| SANDS CAPITAL MANAGEMENT, LLC | 2,755,249 | 0 | 0 | 0 | For |
| Clearbridge Investments, LLC | 0 | 2,303,927 | 0 | 0 | Against |
| Invesco | 1,819,204 | 0 | 0 | 0 | For |
| Rock Springs Capital Management LP | 1,756,055 | 0 | 0 | 0 | For |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 0 | 1,676,811 | 0 | 0 | Against |
| AllianceBernstein | 0 | 1,628,620 | 0 | 0 | Against |
| Hartford | 1,581,556 | 0 | 0 | 0 | For |
| BAKER BROS. ADVISORS LP | 1,466,547 | 0 | 0 | 0 | For |
| Man Group plc | 0 | 1,454,680 | 0 | 0 | Against |
| GEODE CAPITAL MANAGEMENT, LLC | 1,340,869 | 0 | 0 | 0 | For |
| Legg Mason | 0 | 1,333,988 | 0 | 0 | Against |
| Charles Schwab | 987,342 | 0 | 0 | 0 | For |
| TOUCHSTONE FUNDS GROUP TRUST | 776,877 | 0 | 0 | 0 | For |
| First Light Asset Management, LLC | 737,496 | 0 | 0 | 0 | For |
| ALKEON CAPITAL MANAGEMENT LLC | 0 | 693,685 | 0 | 0 | Against |
| Candriam S.C.A. | 0 | 606,897 | 0 | 0 | Against |
| Avidity Partners Management LP | 604,543 | 0 | 0 | 0 | For |
Showing the 25 largest of 320 asset managers. See all 320 in the interactive database.
Combines 3 wordings of this item as funds reported it.
70% Majority: yes · of votes cast
ULTRAGENYX PHARMACEUTICAL INC.’s own tally for this item (“Proposal 2: Approval of the A&R 2023 Plan At the Annual Meeting, the Company's stockholders approved the A&R 2023 Plan. The votes on Proposal 2 were as follows:”): 51,942,752 for, 22,299,718 against, per its Form 8-K filed 2024-06-21 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 83,094,037 outstanding shares: 63% for, 27% against (89% of the company cast a for/against vote).
The 102 asset managers below cast 76% of the shares they voted on this item FOR (24,802,809 for, 7,917,109 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,392,541 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,612,411 | 0 | 0 | 0 | For |
| Fidelity | 1,292,666 | 873,175 | 0 | 0 | For |
| Federated Hermes | 1,882,350 | 0 | 0 | 0 | For |
| BlackRock | 1,744,575 | 0 | 0 | 0 | For |
| Hartford | 1,581,556 | 0 | 0 | 0 | For |
| State Street | 1,558 | 1,515,872 | 0 | 0 | Against |
| Legg Mason | 1,333,988 | 0 | 0 | 0 | For |
| Invesco | 0 | 867,035 | 0 | 0 | Against |
| TOUCHSTONE FUNDS GROUP TRUST | 776,877 | 0 | 0 | 0 | For |
| First Light Asset Management, LLC | 737,496 | 0 | 0 | 0 | For |
| BNY Mellon | 0 | 490,540 | 0 | 0 | Against |
| Charles Schwab | 488,143 | 0 | 0 | 0 | For |
| AllianceBernstein | 0 | 416,360 | 0 | 0 | Against |
| MUTUAL FUND SERIES TRUST | 359,000 | 0 | 0 | 0 | For |
| TIAA | 0 | 335,798 | 0 | 0 | Against |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 331,321 | 0 | 0 | Against |
| Advantage Advisers Xanthus Fund, L.L.C. | 0 | 324,358 | 0 | 0 | Against |
| First Trust | 0 | 280,034 | 0 | 0 | Against |
| John Hancock | 49,165 | 215,422 | 0 | 0 | Against |
| Northwestern Mutual | 259,150 | 0 | 0 | 0 | For |
| MFS | 0 | 256,385 | 0 | 0 | Against |
| Principal | 133,658 | 89,043 | 0 | 0 | For |
| FINANCIAL INVESTORS TRUST | 206,002 | 0 | 0 | 0 | For |
| Goldman Sachs | 0 | 204,203 | 0 | 0 | Against |
Showing the 25 largest of 102 asset managers. See all 102 in the interactive database.
Combines 5 wordings of this item as funds reported it.
92% Majority: yes · of votes cast
ULTRAGENYX PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Corsee Sanders, Ph.D.”): 68,077,817 for, 6,184,030 withheld, per its Form 8-K filed 2024-06-21 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 83,094,037 outstanding shares: 82% for, 7% withheld (89% of the company cast a for/withheld vote).
The 101 asset managers below cast 100% of the shares they voted on this item FOR (28,421,970 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,392,541 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 0 | 2,612,411 | 0 | Abstain |
| Fidelity | 2,165,841 | 0 | 0 | 0 | For |
| Federated Hermes | 1,882,350 | 0 | 0 | 0 | For |
| BlackRock | 1,744,575 | 0 | 0 | 0 | For |
| Hartford | 1,581,556 | 0 | 0 | 0 | For |
| State Street | 1,517,106 | 0 | 324 | 0 | For |
| Legg Mason | 1,333,988 | 0 | 0 | 0 | For |
| Invesco | 867,035 | 0 | 0 | 0 | For |
| TOUCHSTONE FUNDS GROUP TRUST | 776,877 | 0 | 0 | 0 | For |
| BNY Mellon | 490,540 | 0 | 0 | 0 | For |
| Charles Schwab | 488,143 | 0 | 0 | 0 | For |
| AllianceBernstein | 416,360 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 359,000 | 0 | 0 | 0 | For |
| TIAA | 335,798 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 331,321 | 0 | 0 | 0 | For |
| Advantage Advisers Xanthus Fund, L.L.C. | 324,358 | 0 | 0 | 0 | For |
| First Trust | 280,034 | 0 | 0 | 0 | For |
| John Hancock | 215,422 | 0 | 49,165 | 0 | For |
| Northwestern Mutual | 259,150 | 0 | 0 | 0 | For |
| MFS | 256,385 | 0 | 0 | 0 | For |
| Principal | 89,043 | 0 | 133,658 | 0 | Abstain |
| FINANCIAL INVESTORS TRUST | 0 | 0 | 206,002 | 0 | Abstain |
| Goldman Sachs | 0 | 0 | 204,203 | 0 | Abstain |
| Equitable | 159,247 | 0 | 16,828 | 0 | For |
Showing the 25 largest of 101 asset managers. See all 101 in the interactive database.
Combines 5 wordings of this item as funds reported it.
89% Majority: yes · of votes cast
ULTRAGENYX PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Deborah Dunsire, M.D.”): 66,396,499 for, 7,865,348 withheld, per its Form 8-K filed 2024-06-21 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 83,094,037 outstanding shares: 80% for, 9% withheld (89% of the company cast a for/withheld vote).
The 101 asset managers below cast 100% of the shares they voted on this item FOR (26,956,199 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,392,541 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 0 | 2,612,411 | 0 | Abstain |
| Fidelity | 2,144,092 | 0 | 21,749 | 0 | For |
| Federated Hermes | 1,882,350 | 0 | 0 | 0 | For |
| BlackRock | 1,744,575 | 0 | 0 | 0 | For |
| Hartford | 1,581,556 | 0 | 0 | 0 | For |
| State Street | 1,517,106 | 0 | 324 | 0 | For |
| Legg Mason | 1,333,988 | 0 | 0 | 0 | For |
| Invesco | 867,035 | 0 | 0 | 0 | For |
| TOUCHSTONE FUNDS GROUP TRUST | 776,877 | 0 | 0 | 0 | For |
| BNY Mellon | 8,958 | 0 | 481,582 | 0 | Abstain |
| Charles Schwab | 488,143 | 0 | 0 | 0 | For |
| AllianceBernstein | 0 | 0 | 416,360 | 0 | Abstain |
| MUTUAL FUND SERIES TRUST | 359,000 | 0 | 0 | 0 | For |
| TIAA | 335,798 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 0 | 331,321 | 0 | Abstain |
| Advantage Advisers Xanthus Fund, L.L.C. | 324,358 | 0 | 0 | 0 | For |
| First Trust | 280,034 | 0 | 0 | 0 | For |
| John Hancock | 215,422 | 0 | 49,165 | 0 | For |
| Northwestern Mutual | 259,150 | 0 | 0 | 0 | For |
| MFS | 256,385 | 0 | 0 | 0 | For |
| Principal | 7,674 | 0 | 215,027 | 0 | Abstain |
| FINANCIAL INVESTORS TRUST | 0 | 0 | 206,002 | 0 | Abstain |
| Goldman Sachs | 0 | 0 | 204,203 | 0 | Abstain |
| Equitable | 25,857 | 0 | 150,218 | 0 | Abstain |
Showing the 25 largest of 101 asset managers. See all 101 in the interactive database.
Combines 5 wordings of this item as funds reported it.
89% Majority: yes · of votes cast
ULTRAGENYX PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Michael Narachi”): 66,013,202 for, 8,248,645 withheld, per its Form 8-K filed 2024-06-21 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 83,094,037 outstanding shares: 79% for, 10% withheld (89% of the company cast a for/withheld vote).
The 101 asset managers below cast 100% of the shares they voted on this item FOR (26,954,329 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,392,541 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 0 | 2,612,411 | 0 | Abstain |
| Fidelity | 2,144,092 | 0 | 21,749 | 0 | For |
| Federated Hermes | 1,882,350 | 0 | 0 | 0 | For |
| BlackRock | 1,744,575 | 0 | 0 | 0 | For |
| Hartford | 1,581,556 | 0 | 0 | 0 | For |
| State Street | 1,517,106 | 0 | 324 | 0 | For |
| Legg Mason | 1,333,988 | 0 | 0 | 0 | For |
| Invesco | 867,035 | 0 | 0 | 0 | For |
| TOUCHSTONE FUNDS GROUP TRUST | 776,877 | 0 | 0 | 0 | For |
| BNY Mellon | 8,958 | 0 | 481,582 | 0 | Abstain |
| Charles Schwab | 488,143 | 0 | 0 | 0 | For |
| AllianceBernstein | 0 | 0 | 416,360 | 0 | Abstain |
| MUTUAL FUND SERIES TRUST | 359,000 | 0 | 0 | 0 | For |
| TIAA | 335,798 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 0 | 331,321 | 0 | Abstain |
| Advantage Advisers Xanthus Fund, L.L.C. | 324,358 | 0 | 0 | 0 | For |
| First Trust | 280,034 | 0 | 0 | 0 | For |
| John Hancock | 215,422 | 0 | 49,165 | 0 | For |
| Northwestern Mutual | 259,150 | 0 | 0 | 0 | For |
| MFS | 256,385 | 0 | 0 | 0 | For |
| Principal | 7,674 | 0 | 215,027 | 0 | Abstain |
| FINANCIAL INVESTORS TRUST | 0 | 0 | 206,002 | 0 | Abstain |
| Goldman Sachs | 0 | 0 | 204,203 | 0 | Abstain |
| Equitable | 25,857 | 0 | 150,218 | 0 | Abstain |
Showing the 25 largest of 101 asset managers. See all 101 in the interactive database.
Combines 4 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
ULTRAGENYX PHARMACEUTICAL INC.’s own tally for this item (“Proposal 3: Ratification of Selection of Independent Registered Accounting Firm At the Annual Meeting, the Company's stockholders ratified the selection of Ernst & Young LLP as the independent registered public accountin”): 77,155,452 for, 1,362,194 against, per its Form 8-K filed 2024-06-21 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 83,094,037 outstanding shares: 93% for, 2% against (94% of the company cast a for/against vote).
The 101 asset managers below cast 99.9% of the shares they voted on this item FOR (31,968,225 for, 14,128 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,392,541 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,612,411 | 0 | 0 | 0 | For |
| Fidelity | 2,165,841 | 0 | 0 | 0 | For |
| Federated Hermes | 1,882,350 | 0 | 0 | 0 | For |
| BlackRock | 1,744,575 | 0 | 0 | 0 | For |
| Hartford | 1,581,556 | 0 | 0 | 0 | For |
| State Street | 1,517,195 | 235 | 0 | 0 | For |
| Legg Mason | 1,333,988 | 0 | 0 | 0 | For |
| Invesco | 867,035 | 0 | 0 | 0 | For |
| TOUCHSTONE FUNDS GROUP TRUST | 776,877 | 0 | 0 | 0 | For |
| BNY Mellon | 490,540 | 0 | 0 | 0 | For |
| Charles Schwab | 488,143 | 0 | 0 | 0 | For |
| AllianceBernstein | 416,360 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 359,000 | 0 | 0 | 0 | For |
| TIAA | 335,798 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 331,321 | 0 | 0 | 0 | For |
| Advantage Advisers Xanthus Fund, L.L.C. | 324,358 | 0 | 0 | 0 | For |
| First Trust | 280,034 | 0 | 0 | 0 | For |
| John Hancock | 264,587 | 0 | 0 | 0 | For |
| Northwestern Mutual | 259,150 | 0 | 0 | 0 | For |
| MFS | 256,385 | 0 | 0 | 0 | For |
| Principal | 222,701 | 0 | 0 | 0 | For |
| FINANCIAL INVESTORS TRUST | 206,002 | 0 | 0 | 0 | For |
| Goldman Sachs | 204,203 | 0 | 0 | 0 | For |
| Equitable | 176,075 | 0 | 0 | 0 | For |
Showing the 25 largest of 101 asset managers. See all 101 in the interactive database.
98% Majority: yes · of votes cast
ULTRAGENYX PHARMACEUTICAL INC.’s own tally for this item (“Proposal 3: Ratification of Selection of Independent Registered Accounting Firm At the Annual Meeting, the Company's stockholders ratified the selection of Ernst & Young LLP as the independent registered public accountin”): 77,155,452 for, 1,362,194 against, per its Form 8-K filed 2024-06-21 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 83,094,037 outstanding shares: 93% for, 2% against (94% of the company cast a for/against vote).
The 2 asset managers below cast 100% of the shares they voted on this item FOR (29,938 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Simplify Exchange Traded Funds | 28,828 | 0 | 0 | 0 | For |
| Virtus | 1,110 | 0 | 0 | 0 | For |
Ranked by the number of ULTRAGENYX PHARMACEUTICAL INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 83,094,037 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 12.65% |
| 2 | RTW INVESTMENTS, LP | 8.11% |
| 3 | T. Rowe Price | 7.13% |
| 4 | BlackRock | 5.04% |
| 5 | State Street | 4.95% |
| 6 | Federated Hermes | 4.53% |
| 7 | Wellington | 4.51% |
| 8 | Fidelity | 3.51% |
| 9 | SANDS CAPITAL MANAGEMENT, LLC | 3.32% |
| 10 | Clearbridge Investments, LLC | 2.77% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| Vanguard Group | 12.19% | 13F |
| FMR (Fidelity) | 8.77% | 13F |
| BlackRock | 7.73% | 13F |
| Wellington Management | 4.93% | 13F |
| JPMorgan Chase | 4.83% | 13F |
| T. Rowe Price | 4.29% | 13F |
| State Street | 3.43% | 13F |
| Geode Capital | 1.61% | 13F |
| BNY Mellon | 1.10% | 13F |
| Morgan Stanley | 1.10% | 13F |
Percentages above are of 83,094,037 shares outstanding, as reported by ULTRAGENYX PHARMACEUTICAL INC. on its Form 10-Q dated 2024-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ULTRAGENYX PHARMACEUTICAL INC.’s 10-Q dated 2024-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.
At ULTRAGENYX PHARMACEUTICAL INC.'s shareholder meeting held 2024-06-18, in the 2023-2024 proxy season, 324 asset managers reported how they voted in their SEC Form N-PX filings, covering 2,247 separate fund positions. Their filings are grouped here into 7 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — Advisory (non-binding) vote to approve the compensation of our named executive officers. — FOR was 74% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: ULTRAGENYX PHARMACEUTICAL INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2024-06-21.
ULTRAGENYX PHARMACEUTICAL INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.